ArticleJournal of translational medicine2026
Single-cell and multi-omics integrative modeling identifies mitochondrial gene HSPE1 as a therapeutic target in osteosarcoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrative machine learning and multi-omics identify a centromere gene signature and validate B3GALT4 as a tumor suppressor in osteosarcoma.Journal of bone oncology · 2026Article
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
- Letter to the Editor: Single-cell and multi-omics integrative modeling identifies mitochondrial gene HSPE1 as a therapeutic target in osteosarcoma.Journal of translational medicine · 2026Article
- Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMitochondrial metabolism plays a critical role in tumor growth and progression. However, its specific influence on osteosarcoma prognosis remains unclear.
methodsWe conducted univariate Cox regression analysis to identify mitochondrial genes associated with osteosarcoma prognosis. Subsequently, prognostic models predicting overall survival were built using a comprehensive combination of 101 hybrid and 10 machine learning algorithms. In addition, we also evaluated the relationship between the best prognostic model clustering and the clinical characteristics, functional progression, immune microenvironment and immunotherapy of osteosarcoma. Single-cell analysis showed the differences of cell communication in high and low model scores. The expression of the key gene HSPE1 was verified by PCR and immunoblotting in clinical samples. In osteosarcoma cells, HSPE1 was knocked out to verify its effects on osteosarcoma cell proliferation, migration, apoptosis and in vivo tumorigenesis.
resultsThe mitochondrial prognostic index model we constructed is an independent prognostic marker for osteosarcoma, and its ability to predict prognosis is superior to other clinical characteristics and published prognostic features. The high-scoring group was significantly associated with immunosuppression and poor prognosis of immunotherapy, and the signaling pathways that promote tumor progression were significantly enriched. Single-cell analysis showed that TIL infiltration was significantly reduced in the high-scoring group, and CD74-CXCR4 was the main contributing signaling pathway. HSPE1 was identified as a potential therapeutic target for osteosarcoma. PCR and immunoblotting experiments verified that it was highly expressed in osteosarcoma tissues. Knockdown of HSPE1 significantly reduced osteosarcoma cell migration, proliferation, metastasis potential, and increased apoptosis rates. In vivo studies confirmed markedly decreased tumorigenicity following HSPE1 knockout.
conclusionsMIscore reliably identifies high-risk osteosarcoma subgroups. HSPE1 promotes osteosarcoma progression, correlates with immunosuppression, and represents a novel therapeutic target for personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.